Stifel downgraded Agilon Health to Hold from Buy with a price target of $10, down from $21. The firm said the downgrade is due to longer-term structural issues with margins and a near-term lack of visibility on claims, which could continue to weigh on results. Stifel noted that it could become more constructive on the story if it has more clarify on both of these issues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGL:
- Agilon Health (NYSE:AGL) Craters after Slashing FY23 Forecast
- Agilon Health price target lowered by $19 at JPMorgan, here’s why
- Agilon Health just downgraded at Goldman Sachs, here’s why
- Agilon Health initiated with bullish view at JMP Securities, here’s why
- Agilon Health director buys $250K in common stock
